American Oncology Institute

The Oncology Institute Announces Third Quarter 2023 Earnings Release Date and Conference Call

Retrieved on:

Wednesday, October 18, 2023

American Oncology Institute, Eastern Time Zone, Rare-earth element, Internet service provider, Mobile phone

CERRITOS, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2023 financial results after the market close on Wednesday, November 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

Key Points:

CERRITOS, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2023 financial results after the market close on Wednesday, November 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562.
A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671.
The replay will be available until November 15, 2023.

The Oncology Institute Names Jeremy Castle as Chief Operations Officer

Retrieved on:

Wednesday, October 11, 2023

Pharmacy, MBA, American Oncology Institute, Castle, Patient, History, Management, Oncology

CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023.

Key Points:

CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023.
He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urology Group and Executive Director for The US Oncology Network.
“We are thrilled to welcome Jeremy to TOI as our Chief Operations Officer,” shared Chief Executive Officer, Dr. Daniel Virnich.
“As Chief Operations Officer, I will have the opportunity to serve TOI’s patients, teammates, community, and shareholders.

The Oncology Institute Executive Leaders to Present at the 2023 Association for Value-Based Cancer Care (AVBCC) Summit

Retrieved on:

Tuesday, September 26, 2023

Competition, Oncology, American Oncology Institute, CMO, Conglomerate, Management, Tobacco

CERRITOS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (TOI) is excited to announce that multiple executives including CEO, Dr. Daniel Virnich, CMO, Dr. Yale Podnos, and other senior clinical leaders, will be participating in the Association for Value-Based Cancer Care (AVBCC) Summit.

Key Points:

CERRITOS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (TOI) is excited to announce that multiple executives including CEO, Dr. Daniel Virnich, CMO, Dr. Yale Podnos, and other senior clinical leaders, will be participating in the Association for Value-Based Cancer Care (AVBCC) Summit.
The 2023 AVBCC Summit features keynote speakers, interactive panel discussions, and informative sessions designed to foster collaboration, innovation and progress in the field of value-based cancer care.
The industry-leading conference is scheduled to take place October 18-20 at the New York Athletic Club in New York City.
For more information about the 2023 AVBCC Summit, including registration details and the full agenda, please visit valuebasedcancer.com/avbcc/2023-summit .

The Oncology Institute Regains Compliance with Nasdaq Listing Requirements

Retrieved on:

Monday, September 18, 2023

American Oncology Institute, Rule, Cryptocurrency, Auction

CERRITOS, California, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI) (the “Company”), one of the largest value-based community oncology groups in the United States, today announced that it received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) on September 15, 2023, informing the Company that it has regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.

Key Points:

CERRITOS, California, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI) (the “Company”), one of the largest value-based community oncology groups in the United States, today announced that it received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) on September 15, 2023, informing the Company that it has regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.
This follows second quarter 2023 results demonstrating continued strong year over year revenue growth, and announcements on recent technology partnerships with Ambience Healthcare and Massive Bio to drive continued efficiencies and expansion of the business.
To regain compliance with the Rule, the Company’s common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.
This requirement was met on September 14, 2023.

The Oncology Institute Partners with House Rx to Accelerate Growth of Pharmacy Operations

Retrieved on:

Monday, July 31, 2023

American Oncology Institute, Pharmacy, Pharmacist, Patient, SAN, Growth, Entrepreneurship, House, Hospital

House Rx provides clinics with specialized technology and services support from pharmacists and care coordinators.

Key Points:

House Rx provides clinics with specialized technology and services support from pharmacists and care coordinators.
House Rx staff are integrated with the clinic to help patients start therapy as quickly as possible and drive adherence to treatment for better outcomes.
TOI’s alignment with House Rx will expand patient access to oral specialty medications via TOI dispensary and pharmacy locations, and enhance in-office dispensary operations.
“By partnering with House Rx, we will accelerate the growth of our clinic-based oral drug dispensing capabilities and improve our ability to add pharmacy locations in California and Texas that will allow us to access patient populations that we previously could not serve,” said Dr. Daniel Virnich, CEO of The Oncology Institute.

The Oncology Institute Announces Second Quarter 2023 Earnings Release Date and Conference Call

Retrieved on:

Tuesday, July 18, 2023

American Oncology Institute, Eastern Time Zone, Rare-earth element, Satellite navigation device, Cryptocurrency

CERRITOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2023 financial results after the market close on Tuesday, August 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

Key Points:

CERRITOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2023 financial results after the market close on Tuesday, August 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562.
A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671.
The replay will be available until August 15, 2023.

The Oncology Institute Announces Leadership Transition

Retrieved on:

Monday, June 12, 2023

American Oncology Institute, Culture, Patient, DaVita Inc., Growth, Health, Northeast Florida Regional Airport, Management, Nursing

Mr. Hively will transition to the role of Vice Chairman of the Board of Directors.

Key Points:

Mr. Hively will transition to the role of Vice Chairman of the Board of Directors.
Dr. Daniel Virnich has been with The Oncology Institute since 2020, initially as Chief Operating Officer before being promoted to President.
Under his leadership, TOI evolved from a privately held regional oncology practice into a publicly traded national leader in value-based oncology.
As Vice Chairman I will focus my efforts on TOI’s strategic partnerships, growth opportunities, talent development, and governance.”

The Oncology Institute (TOI) and Massive Bio Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

Retrieved on:

Friday, June 9, 2023

Partnership, American Oncology Institute, Clinical trial, Cancer, Hope, Intelligence, Research, Patient, Physician, Algorithm, Medicine, AI, Medical device

CERRITOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), has announced a non-exclusive partnership with Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients.

Key Points:

CERRITOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), has announced a non-exclusive partnership with Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients.
This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network.
Cristina Green, VP of Clinical Research at TOI, commented, “We are excited to announce our partnership with Massive Bio.
With our forces joined, more patients will be able to access the most advanced precision medicine available, revolutionizing cancer care.

The Oncology Institute to Open Project Southland

Retrieved on:

Wednesday, June 7, 2023

SRON, American Oncology Institute, Radiation, Transport, Acquisition, MBA, MD, Patient, Medical imaging, Greater Los Angeles

The acquisition of Southland Radiation Oncology Network (SRON) will amplify TOI's radiation oncology market presence by five additional clinics across the eastern San Gabriel Valley and Inland Empire, providing TOI with a distinct advantage over local private practices and tertiary centers.

Key Points:

The acquisition of Southland Radiation Oncology Network (SRON) will amplify TOI's radiation oncology market presence by five additional clinics across the eastern San Gabriel Valley and Inland Empire, providing TOI with a distinct advantage over local private practices and tertiary centers.
The acquisition of SRON is an important milestone for TOI as they continue to expand their ability to provide complete population health for oncology care.
"We are thrilled to be taking this next step in our journey as we expand our radiation oncology practice locations, and look forward to serving the community with the highest quality of care," said Dan Virnich, MD, MBA, FACHE, President of The Oncology Institute.
The acquisition of SRON will enable TOI to offer value-based radiation oncology care to more patients in the Greater Los Angeles area.

Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

Retrieved on:

Saturday, June 3, 2023

Massive Bio , a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI) , a premier provider of cutting-edge cancer care.

Key Points:

Massive Bio , a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI) , a premier provider of cutting-edge cancer care.
View the full release here: https://www.businesswire.com/news/home/20230603005001/en/
Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research (Photo: Business Wire)
Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI's active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine.
"We are incredibly excited about joining forces with The Oncology Institute ," said Selin Kurnaz, Ph.D., CEO of Massive Bio.
Furthermore, this collaboration will expand the scope of cancer research through Massive Bio's recent ChatGPT-powered chatbots for oncology research release during ASCO 2023.